Difference between revisions of "Team:UCSC/Acetaminophen"
Evan pepper (Talk | contribs) |
|||
| Line 1: | Line 1: | ||
| − | {{UCSC-Header}} | + | <!-- {{UCSC-Header}} --> |
| + | {{HEADER-FINAL}} | ||
| + | |||
<html> | <html> | ||
| + | |||
<style> | <style> | ||
| + | |||
.metabolic-pathway { | .metabolic-pathway { | ||
margin: auto; | margin: auto; | ||
| Line 7: | Line 11: | ||
width: 85%; | width: 85%; | ||
} | } | ||
| + | |||
h1 { | h1 { | ||
| − | font-family: | + | font-family: 'objektiv-mk1'!important; |
| − | + | ||
font-size: 400%; /*!important*/ | font-size: 400%; /*!important*/ | ||
} | } | ||
| + | |||
#page { | #page { | ||
background: honeydew; | background: honeydew; | ||
| Line 53: | Line 58: | ||
color: black; | color: black; | ||
font-size: 20px; | font-size: 20px; | ||
| − | + | padding: 16px 32px; | |
} | } | ||
.paragraph-left { | .paragraph-left { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
| − | + | ||
font-size: 18px; | font-size: 18px; | ||
text-align: left; | text-align: left; | ||
| Line 65: | Line 69: | ||
p { | p { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
/* margin-left: 200px !important; | /* margin-left: 200px !important; | ||
margin-right: 200px !important;*/ | margin-right: 200px !important;*/ | ||
| Line 72: | Line 76: | ||
.firstword { | .firstword { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 100px; | font-size: 100px; | ||
} | } | ||
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
font-size: 40px; | font-size: 40px; | ||
| Line 82: | Line 86: | ||
.quote-person { | .quote-person { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 27px; | font-size: 27px; | ||
width: 100% !important; | width: 100% !important; | ||
| Line 98: | Line 102: | ||
.reference-list { | .reference-list { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; |
font-size: 12px; | font-size: 12px; | ||
text-align: left; | text-align: left; | ||
| Line 107: | Line 111: | ||
.reference-italic { | .reference-italic { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; |
font-size: 12px; | font-size: 12px; | ||
font-style: italic; | font-style: italic; | ||
| Line 113: | Line 117: | ||
figcaption { | figcaption { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; |
font-style: italic; | font-style: italic; | ||
font-size: 13px; | font-size: 13px; | ||
| Line 121: | Line 125: | ||
@media (min-width: 1144px) { | @media (min-width: 1144px) { | ||
.container { | .container { | ||
| − | width: | + | width: 70% !important; |
} | } | ||
.text-container { | .text-container { | ||
| − | width: | + | width: 70%; |
padding-left: 15px; | padding-left: 15px; | ||
padding-right: 15px; | padding-right: 15px; | ||
| Line 143: | Line 147: | ||
p { | p { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
margin-left: 10px !important; | margin-left: 10px !important; | ||
margin-right: 10px !important; | margin-right: 10px !important; | ||
| Line 150: | Line 154: | ||
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
font-size: 30px; | font-size: 30px; | ||
| Line 156: | Line 160: | ||
.quote-person { | .quote-person { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 23px; | font-size: 23px; | ||
width: 100%; | width: 100%; | ||
| Line 170: | Line 174: | ||
.container { | .container { | ||
| − | width: | + | width: 80% !important; |
padding-left: 0px !important; | padding-left: 0px !important; | ||
padding-right: 0px !important; | padding-right: 0px !important; | ||
| Line 176: | Line 180: | ||
.text-container { | .text-container { | ||
| − | width: | + | width: 80%; |
padding-left: 0px; | padding-left: 0px; | ||
padding-right: 0px; | padding-right: 0px; | ||
| Line 207: | Line 211: | ||
h1 { | h1 { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; /*!important*/ |
| − | + | ||
font-size: 250%; /*!important*/ | font-size: 250%; /*!important*/ | ||
} | } | ||
h2 { | h2 { | ||
| − | font-family: | + | font-family: 'objektiv-mk1'; /*!important*/ |
| − | + | ||
font-size: 20px; /*!important*/ | font-size: 20px; /*!important*/ | ||
} | } | ||
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
font-size: 20px; | font-size: 20px; | ||
| Line 226: | Line 228: | ||
.quote-person { | .quote-person { | ||
width: 100%; | width: 100%; | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 16px; | font-size: 16px; | ||
text-align: right !important; | text-align: right !important; | ||
| Line 233: | Line 235: | ||
.text-container { | .text-container { | ||
| − | width: | + | width: 82%; |
padding-left: 0px; | padding-left: 0px; | ||
padding-right: 0px; | padding-right: 0px; | ||
| Line 270: | Line 272: | ||
.firstword { | .firstword { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 70px; | font-size: 70px; | ||
} | } | ||
| Line 281: | Line 283: | ||
p { | p { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
margin-left: 20px !important; | margin-left: 20px !important; | ||
margin-right: 20px !important; | margin-right: 20px !important; | ||
| Line 292: | Line 294: | ||
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
font-size: 17px; | font-size: 17px; | ||
| Line 299: | Line 301: | ||
.quote-person { | .quote-person { | ||
width: 60% !important; | width: 60% !important; | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 12px; | font-size: 12px; | ||
text-align: right !important; | text-align: right !important; | ||
| Line 311: | Line 313: | ||
.text-container { | .text-container { | ||
| − | width: | + | width: 85%; |
padding-left: 0px; | padding-left: 0px; | ||
padding-right: 0px; | padding-right: 0px; | ||
| Line 351: | Line 353: | ||
<div class="quote-person"> ~Clinical Manual of Fever in Children</div> | <div class="quote-person"> ~Clinical Manual of Fever in Children</div> | ||
</div> | </div> | ||
| + | |||
<br> | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | |||
<div class="metabolic-pathway"> | <div class="metabolic-pathway"> | ||
<img src="https://static.igem.org/mediawiki/2017/0/02/Ace_pathway.png" style="width: 75%;"> | <img src="https://static.igem.org/mediawiki/2017/0/02/Ace_pathway.png" style="width: 75%;"> | ||
</div> | </div> | ||
| + | |||
<br> | <br> | ||
| + | <br> | ||
| + | |||
<div class="text-container"> | <div class="text-container"> | ||
<div class="paragraph-left"> | <div class="paragraph-left"> | ||
| − | We aim to genetically modify | + | We aim to genetically modify PCC 7942 to produce acetaminophen, a common mild anesthetic and antipyretic recognized by the WHO as an essential medicine <sup>[1]</sup>. However, in many countries with lower regulations and faulty policies regarding drug manufacturing, acetaminophen can be synthesized with lethal toxins that result in hundreds of deaths worldwide <sup>[23]</sup>. Acetaminophen is oftenused in conjunction with opioid pain medications postoperatively to enhance pain relief, thus reducing reliance upon opioid pharmaceuticals <sup>[24]</sup>. |
</div> | </div> | ||
</div> | </div> | ||
| + | |||
<!-- <div class="container"> | <!-- <div class="container"> | ||
<div class="row"> | <div class="row"> | ||
| Line 366: | Line 376: | ||
<figure> | <figure> | ||
<img src="https://static.igem.org/mediawiki/2017/7/79/Pathway_%281%29.png" style="width: 100%;"> | <img src="https://static.igem.org/mediawiki/2017/7/79/Pathway_%281%29.png" style="width: 100%;"> | ||
| − | <figcaption style="font-family: ' | + | <figcaption style="font-family: 'objektiv-mk1'; font-style: italic; font-size: 13px;">Current synthetic biology approach to manufacturing acetaminophen in E.coli <sup>[25, 26]</sup>.Genes 4ABH and nhoA were inserted to synthesize the pathway in PCC 7942. The gene from A.bisporus, 4ABH, produces 4-aminophenol while the E. coli gene nhoA converts that 4-aminophenol to acetaminophen <sup>[25]</sup>.</figcaption> |
</figure> | </figure> | ||
</div> | </div> | ||
| Line 376: | Line 386: | ||
</div> | </div> | ||
</div> --> | </div> --> | ||
| + | |||
<div class="container"> | <div class="container"> | ||
<div class="row"> | <div class="row"> | ||
<figure> | <figure> | ||
<img src="https://static.igem.org/mediawiki/2017/7/79/Pathway_%281%29.png" style="width: 100%;"> | <img src="https://static.igem.org/mediawiki/2017/7/79/Pathway_%281%29.png" style="width: 100%;"> | ||
| − | <figcaption>Current synthetic biology approach to manufacturing acetaminophen in < | + | <figcaption>Current synthetic biology approach to manufacturing acetaminophen in <span style="font-style: italic";>E. coli</span> <sup>[25, 26]</sup>. Genes <span style="font-style: italic";>4ABH</span> and <span style="font-style: italic";>nhoA</span> were inserted to synthesize the pathway in PCC 7942. The gene from <span style="font-style: italic";>A. bisporus, 4ABH</span>, produces 4-aminophenol while the <span style="font-style: italic";>E. coli</span> gene <span style="font-style: italic";>nhoA</span> converts that 4-aminophenol to acetaminophen <sup>[25]</sup>.</figcaption> |
</figure> | </figure> | ||
</div> | </div> | ||
</div> | </div> | ||
| + | |||
<br> | <br> | ||
<br> | <br> | ||
| − | + | <br> | |
| − | + | <br> | |
| − | + | <div class="text-container"> | |
| + | <div class="paragraph-left"> | ||
| + | We are using a previously engineered pathway in <span style="font-style: italic";>E. coli</span> as a model of acetaminophen biosynthesis to enhance PCC 7942 <sup>[26, 25]</sup>. The pathway converts chorismate, an abundant aminoacid precursor of tryptophan, phenylalanine, and tyrosine, into acetaminophen with the addition ofthe <span style="font-style: italic";>4ABH</span> gene from <span style="font-style: italic";>A. bisporus</span>, an edible mushroom, and <span style="font-style: italic";>nhoA</span> from <span style="font-style: italic";>E. coli</span>. | ||
| + | </div> | ||
</div> | </div> | ||
| − | + | ||
<br> | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | |||
<div class="container"> | <div class="container"> | ||
<div class="reference-list"> | <div class="reference-list"> | ||
Revision as of 20:59, 14 October 2017
Acetaminophen Metabolics
"Antipyretic drugs, by being analgesics, reduce not only the fever but also the pain."
~Clinical Manual of Fever in Children
We aim to genetically modify PCC 7942 to produce acetaminophen, a common mild anesthetic and antipyretic recognized by the WHO as an essential medicine [1]. However, in many countries with lower regulations and faulty policies regarding drug manufacturing, acetaminophen can be synthesized with lethal toxins that result in hundreds of deaths worldwide [23]. Acetaminophen is oftenused in conjunction with opioid pain medications postoperatively to enhance pain relief, thus reducing reliance upon opioid pharmaceuticals [24].
We are using a previously engineered pathway in E. coli as a model of acetaminophen biosynthesis to enhance PCC 7942 [26, 25]. The pathway converts chorismate, an abundant aminoacid precursor of tryptophan, phenylalanine, and tyrosine, into acetaminophen with the addition ofthe 4ABH gene from A. bisporus, an edible mushroom, and nhoA from E. coli.
